GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » PEG Ratio

Apollon Formularies (AQSE:APOL) PEG Ratio : N/A (As of Jun. 06, 2024)


View and export this data going back to . Start your Free Trial

What is Apollon Formularies PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Apollon Formularies's PE Ratio without NRI is 0.00. Apollon Formularies's 5-Year EBITDA growth rate is 0.00%. Therefore, Apollon Formularies's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Apollon Formularies's PEG Ratio or its related term are showing as below:



AQSE:APOL's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.63
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Apollon Formularies PEG Ratio Historical Data

The historical data trend for Apollon Formularies's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies PEG Ratio Chart

Apollon Formularies Annual Data
Trend Jun10 Jun11 Dec12 Dec13 Dec14 Dec17 Dec18 Dec19 Dec20 Dec21
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Apollon Formularies Semi-Annual Data
Jun11 Jun12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Jun23
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Apollon Formularies's PEG Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Apollon Formularies's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apollon Formularies's PEG Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apollon Formularies's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Apollon Formularies's PEG Ratio falls into.



Apollon Formularies PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Apollon Formularies's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


Apollon Formularies  (AQSE:APOL) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Apollon Formularies PEG Ratio Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollon Formularies (AQSE:APOL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS
Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.

Apollon Formularies (AQSE:APOL) Headlines

From GuruFocus

FPA Capital Fund Comments on Apollo Education Group Inc

By Vera Yuan Vera Yuan 02-19-2015

FPA Capital Fund new buys in Q2 2015

By Tiziano Frateschi Tiziano Frateschi 07-14-2015

Apollo Group: This Unloved Company Is Significantly Undervalued

By Matthew Dow Matthew Dow 05-09-2013

The Yacktman Focused Fund's Top Growth Stocks

By Dianne Tordillo Dianne Tordillo 01-25-2013

Yacktman Fund Comments on Apollo

By Holly LaFon Holly LaFon 02-05-2016

5 Stocks to Avoid - January 2017

By Benjamin Clark Benjamin Clark 01-14-2017

FPA Capital Fund Q1 2013 Commentary

By Holly LaFon Holly LaFon 04-24-2013

7 Arbitrage Trades With High Profit Potential

By Jonathan Poland Jonathan Poland 11-30-2016

Apollo Group Inc. Reports 10-Q Quarterly Operating Results

By gurufocus gurufocus 06-26-2012

Update from FPA Capital - Seven Changes to Portfolio

By Sally Jones Sally Jones 07-14-2013